drugset / Trial / NCT01043666

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666

Phase 3 Completed 1126 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.

Timeline

Start
2009-12-21
Primary completion
2011-09-16
Completion
2011-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified Oral
Subject Tolterodine Small molecule Oral

Indications